Zoetis (BSP:Z1TS34) Common Stock : R$24 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Zoetis Common Stock?

Zoetis's quarterly common stock increased from Jun. 2023 (R$24 Mil) to Sep. 2023 (R$25 Mil) but then declined from Sep. 2023 (R$25 Mil) to Dec. 2023 (R$24 Mil).

Zoetis's annual common stock declined from Dec. 2021 (R$28 Mil) to Dec. 2022 (R$26 Mil) and declined from Dec. 2022 (R$26 Mil) to Dec. 2023 (R$24 Mil).

Zoetis Common Stock Historical Data

The historical data trend for Zoetis's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Common Stock Chart

Zoetis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

20.52

25.72

28.27

26.23

24.50

Zoetis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															26.23	26.04	24.27	24.69	24.50

Zoetis Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Zoetis (BSP:Z1TS34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (BSP:Z1TS34) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ZTS:USA ZTS:Mexico 1ZTS:Italy ZOE:Germany

Address

10 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.zoetis.com

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis (BSP:Z1TS34) Headlines

No Headlines